Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSHCER T Cells in Recurrent Ovarian Cancer
NCT05316129Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2022
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of FSHR-mediated CAR-T in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (10 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 day. Started Apr 2022; status: recruiting.
02
Drugs
FSHR-mediated CAR-T
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05316129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316129.